ArticleArchives of dermatological research2025
Astragalin inhibits fibroblast proliferation, motion, and ECM synthesis and regulates the MAPK pathway in keloid.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A panoramic analysis of keloid pathogenesis: multidimensional network regulation of genetics-immunity-metabolism-mechanical force.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keloid is a fibroproliferative skin disorder characterized by fibroblast hyperproliferation and excessive extracellular matrix (ECM) deposition. Astragalin (AST) is a bioactive natural flavonoid with multiple pharmacological properties. This study aims to investigate the effect of AST on keloid formation in vitro. Primary keloid fibroblasts (KFs) and normal fibroblasts (NFs) were isolated from human keloid tissues and normal skin tissues, respectively, and treated with or without AST. MTT, colony formation, and Transwell assays were utilized to evaluate AST's effect on fibroblast proliferation, migration, and invasiveness. Western blotting was implemented for detecting protein levels of ECM components and mitogen-activated protein kinases (MAPKs). The results showed that AST treatment hindered the proliferative, migratory, and invasive capacities of KFs and NFs, and KFs were more sensitive to AST than NFs. AST restrained ECM deposition and inactivated the MAPK signaling pathway in KFs and NFs. In conclusion, AST suppresses the invasive growth of keloid fibroblasts probably by inactivating MAPK signaling.
Indexed as
Identifiers
40105997What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.